Indications / MP1032 Pipeline
1 Recently received Orphan Drug Designation and Rare Pediatric Disease Designation from FDA in 2023; further orphan muscular dystrophy indications such as e.g. Becker's Muscular Dystrophy with similar standard anti-inflammatory therapy
2 Systemic JIA is a rare and serious subtype of JIA that causes body-wide inflammation (incl. the liver, lungs and heart)
3 Phase IIa financed by EU grant of EUR7.9m; data were published in Lancet Regional Health (Europe); this study could serve as PoC for Host-Directed Therapies for potentially pandemic infectious diseases such as COVID-19, RSV, Influenza ("Pandemic Preparedness")
4 E.g. Sepsis, Multi Drug Resistant Infections, Clostridioides difficile, Acute Respiratory Distress Syndrome (ARDS)